Earnings ·
Madrigal Pharmaceuticals reported second-quarter 2026 financial results with net revenues of $364.3 million, a 71%…
MDGLMadrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals reported second-quarter 2026 financial results with net revenues of $364.3 million, a 71% increase year-over-year, driven by strong demand for Rezdiffra in the U.S. The company surpassed 50,000 active patients on its MASH treatment and strengthened its intellectual property portfolio with three new patents extending protection into 2042-2045. Operating expenses rose to $420.6 million due to commercial expansion and $25.0 million in one-time business development costs, resulting in a net loss of $57.9 million or $1.99 per share. The company ended the quarter with $838.9 million in cash and marketable securities. Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH).